Opus Genetics (NASDAQ:IRD) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Opus Genetics (NASDAQ:IRD) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

Several other research analysts have also recently commented on the stock. Guggenheim began coverage on shares of Opus Genetics in a report on Thursday, June 4th. They issued a “buy” rating and a $16.00 target price for the company. Citizens Jmp restated a “market outperform” rating and set a $11.00 price target on shares of Opus Genetics in a report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research report on Friday, July 17th. B. Riley Financial reaffirmed a “buy” rating on shares of Opus Genetics in a research note on Thursday, April 30th. Finally, Chardan Capital reiterated a “buy” rating and set a $13.00 price objective on shares of Opus Genetics in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Opus Genetics currently has an average rating of “Moderate Buy” and a consensus price target of $10.69.

Opus Genetics Price Performance

Shares of NASDAQ IRD opened at $3.61 on Friday. Opus Genetics has a 12 month low of $1.10 and a 12 month high of $5.81. The company has a market cap of $298.37 million, a price-to-earnings ratio of -2.67 and a beta of 0.59. The business has a fifty day simple moving average of $3.76 and a 200-day simple moving average of $4.16.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $2.63 million. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%. As a group, sell-side analysts expect that Opus Genetics will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling at Opus Genetics

In other news, CEO George Magrath sold 9,475 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the transaction, the chief executive officer owned 1,731,869 shares in the company, valued at $5,109,013.55. This represents a 0.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 29,331 shares of company stock valued at $86,629. 11.70% of the stock is owned by corporate insiders.

Institutional Trading of Opus Genetics

Several institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL lifted its position in Opus Genetics by 12.3% in the 4th quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock worth $55,000 after buying an additional 3,000 shares in the last quarter. Raymond James Financial Inc. grew its holdings in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock valued at $37,000 after acquiring an additional 11,000 shares in the last quarter. Occudo Quantitative Strategies LP purchased a new position in shares of Opus Genetics during the 4th quarter valued at $25,000. Stoneridge Investment Partners LLC purchased a new position in shares of Opus Genetics during the 2nd quarter valued at $47,000. Finally, State of Wyoming acquired a new position in shares of Opus Genetics in the second quarter worth $65,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.

Key Opus Genetics News

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast, indicating a more favorable view of Opus Genetics’ expected financial performance. The revision may support investor sentiment, although the updated forecast remains a loss. Opus Genetics FY2026 EPS Forecast Lifted by HC Wainwright
• Positive Sentiment: Brookline Capital Markets raised its Opus Genetics EPS estimates for Q3 2026 to a loss of $0.15 per share from $0.18, FY2026 to a loss of $0.87 from $1.31, FY2027 to a loss of $0.56 from $0.77, and FY2028 to a loss of $0.61 from $0.68. These revisions imply reduced expected losses over the next several years. Brookline Capital Markets Estimates Opus Genetics FY2030 Earnings
• Positive Sentiment: Zacks Research upgraded Opus Genetics from “strong sell” to “hold.” While this is not a bullish buy recommendation, the removal of the strongest negative rating may reduce selling pressure and improve sentiment. Zacks.com
• Neutral Sentiment: Brookline’s current projections call for continued losses, including EPS of negative $0.87 in FY2026, negative $0.56 in FY2027, negative $0.61 in FY2028, and negative $0.71 in FY2029. The improved forecasts are encouraging, but they do not yet indicate profitability. Brookline Capital Markets estimates

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.